Jamie Kang

[Tissue Barriers] Researchers performed an integrative analysis of 177 RNA-Seq datasets from TCGA and GTEx to characterize Claudin family alterations in PDAC.

[Gene] The authors summarize current knowledge on the multifaceted roles of ncRNAs across major cellular compartments of the tumor microenvironment, highlight key barriers that limit their diagnostic and therapeutic potential, and discuss emerging strategies that may accelerate the development of ncRNA-guided precision medicine in PDAC.

[BridgeBio Oncology Therapeutics, Inc.] BridgeBio Oncology Therapeutics, Inc. announced that the US FDA has granted Fast Track designation to BBO-11818 for the treatment of adult patients with advanced KRAS-mutant pancreatic ductal adenocarcinoma.

[ACS Nano] Researchers developed ND-dsRNA-VHH, a biocompatible carbon-based nanomaterial platform that codelivers EGFR-specific nanobodies (VHHs) and immunostimulatory double-stranded RNA, polyinosinic–polycytidylic acid (poly(I:C)).

[Genome Biology] Investigators analyzed paired baseline and post-treatment tumor samples from 50 patients with stage II–III TNBC treated with anthracycline- and taxane-based neoadjuvant chemotherapy, integrating whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics.

[Journal for Immunotherapy of Cancer] Scientists defined a new mechanism of barrier-mediated immune exclusion in cancer controlled by TROP2-dependent tight junctions. This mechanism drives tumor progression but can be targeted via TROP2-directed therapy to activate antitumor immunity and enhance immunotherapy response.